logo
‘Appalling breach of public trust': Mass. State Rep charged in fraud and cover-up scheme, feds say

‘Appalling breach of public trust': Mass. State Rep charged in fraud and cover-up scheme, feds say

Yahoo11-04-2025

A Massachusetts State Representative has been arrested for a fraud and cover-up scheme that allegedly defrauded a trade association of tens of thousands of dollars, the United States District Attorney for Massachusetts Leah Foley announced Friday.
Christopher Flanagan, 37, the state representative for the First Barnstable District (representing Dennis, Yarmouth and Brewster) is accused of stealing funds from the Home Builders Association in Cape Cod while he served as Executive Officer in order to pay his mortgage and buy other personal items.
Flanagan was arrested Friday morning and will appear in Boston federal court Friday afternoon on five counts of wire fraud and one charge of falsification of records, Foley said.
Foley alleges that Flanagan had thousands of dollars in credit card debt, was missing mortgage payments and had hundreds of dollars in bank overdraft fees at the time of the alleged scheme.
In January 2023, Flanagan allegedly stole $10,000 from the HBA to fund his campaign for state representative.
'It is further alleged that, in addition to stealing HBA funds via official checks and PayPal transfers, Flanagan also stole hundreds of dollars via direct debit transactions from the association's bank account funds to pay for personal psychic services in July 2022,' Foley states.
Flanagan allegedly tried to conceal the stolen funds by logging onto HBA's accounting/bookkeeping software using another employee's account and entering backdated transactions and false transaction codes to account for the stolen funds.
Flanagan allegedly told the HBA Board that he withdrew the funds to compensate himself for HBA-related expenses that he said he had previously paid for out of pocket.
Flanagan allegedly provided two phony expense reports when questioned by the HBA Board. On one expense report, Flanagan allegedly claimed he had spent $159.36 on 'Technology Expenses' at Best Buy and another $537.26 on 'Office Supplies' at 4Imprint. However, records show the Best Buy purchase was for a portable Bluetooth speaker and that the 4Imprint purchase was for t-shirts supporting Flanagan's State Representative campaign, according to Foley.
In the second expense report for $3,784.84 of 'Office Supplies,' Flanagan's $613.70 and $361.24 Best Buy purchases were allegedly for an electric dryer and an air conditioner. Additionally, a $1,050.30 Macy's purchase was allegedly for men's ties, dress shirts, slacks and sports coats; and a $92.86 purchase at Target was allegedly used on children's clothes and toys.
Flanagan also allegedly constructed a fake identity, 'Jeanne Louise,' while he operated a campaign mailer during his 2022 campaign. After admitting to OCPF that Jeanne Louise was fake and that he himself was the source of the mailer, OCPF expanded its investigation into Flanagan's campaign finance activity.
The OCPF then requested that Flanagan produce evidence that the $10,000 deposited into his campaign account in January 2023 had indeed come from his personal funds.
However, according to Foley, Flanagan's bank statements at the time showed he only had $42.28 in his account - showing he could not have deposited the $10,000 campaign check without stealing the HBA money. Flanagan allegedly provided OCPF with another falsified expense reports that claimed that 'the $10,000 check from HBA constituted legitimate HBA-reimbursed expenses; that HBA had a practice of allowing Flanagan to withdraw large sums of money for the purpose of expense reimbursement; and therefore, the $10,000 campaign check was a legitimate donation of Flanagan's own personal funds,' according to Foley.
'Today's charges against Massachusetts State Representative Christopher Flanagan reveal an appalling breach of public trust. According to the indictment, Mr. Flanagan defrauded the very organization he was supposed to serve – allegedly funneling tens of thousands of dollars into his own pockets to pay off personal bills, buy luxury items and bankroll his political campaign. He allegedly stole money and then went to extraordinary lengths to cover it up, going so far as fabricating fake personas to mislead those who questioned his conduct. This alleged scheme was calculated on every level,' said United States Attorney Leah B. Foley. 'No one is entitled to power by way of fraud, and the people of Massachusetts deserve better.'
Governor Maura Healey called for Flanagan to resign from this post.
'These are serious allegations against Representative Flanagan that threaten to undermine the important work of the Legislature and cast doubt on his ability to faithfully serve his constituents. He should resign,' Healey said in a statement.
In January, Barnstable police announced in January they received a complaint alleging of 'potential criminal activity' involving Flanagan.
The charges of wire fraud each provide for a sentence of up to 20 years in prison, three years of supervised release and a fine of up to $250,000. The charge of falsification of records provides for a sentence of up to 20 years in prison, three years of supervised release and a fine of up to $250,000.
Download the FREE Boston 25 News app for breaking news alerts.
Follow Boston 25 News on Facebook and Twitter. | Watch Boston 25 News NOW

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

If You Still Need To Shop for Dad, These Gift Card Deals Have You Covered
If You Still Need To Shop for Dad, These Gift Card Deals Have You Covered

CNET

time42 minutes ago

  • CNET

If You Still Need To Shop for Dad, These Gift Card Deals Have You Covered

A gift card is always a reliable, safe gifting option that suits every recipient, including dads. And with Father's Day just days away, a digital gift card is guaranteed to be just what they need and arrive on time. Digital gift cards can even be printed and wrapped or placed inside a card, if you need something on hand. Right now, on Amazon and Best Buy, you can choose from many companies and save big. This includes gift cards to Uber, DoorDash, Adidas and more. Father's Day is this weekend, so act fast if you're interested. Amazon has a large selection of gift cards that fathers will love. For example, a Lyft card can help him get around, and you can save $15 on a $100 gift card, meaning you'll pay just $85. If he prefers Uber, you're in luck. You can save $5 on a $50 gift card, so you'll pay just $45. This card works for Uber and Uber Eats. (Cards can be split, too. This means if you opt for multiple $25 cards, you'll still qualify for the discount.) And if he needs help getting back into the dating pool, you can get him a Tinder card, valid for one month of Tinder Gold. This $39 service can be purchased for $28, a savings of $11. Hey, did you know? CNET Deals texts are free, easy and save you money. Best Buy also has many options. The movie-loving dad will enjoy a Regal gift card. You can save $15 on a $100 gift card, reducing the cost to $85. Golfing dads will love an NBC GolfNow card, and you can save $8 to score a $50 gift card for just $43. And for the foodies in the bunch, you can save $15 on a $100 DoorDash gift card, discounting the price to $85. Why this deal matters Gift cards make the perfect gift for anyone because they can be tailored to any interest. And since Father's Day is two days away, choices are becoming more limited. But, these gift cards are up to 20% off right now at both Amazon and Best Buy. Plus, the selection is pretty big, so you'll surely find something your dad will appreciate.

Billions in Deals Reshaping the Cell and Gene Therapy Industry, reports Kalorama Information
Billions in Deals Reshaping the Cell and Gene Therapy Industry, reports Kalorama Information

Yahoo

time2 hours ago

  • Yahoo

Billions in Deals Reshaping the Cell and Gene Therapy Industry, reports Kalorama Information

ARLINGTON, Va., June 13, 2025 /PRNewswire/ -- Kalorama Information, a leading publisher of life sciences market research, has released the highly anticipated third edition of its landmark report, Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025. This comprehensive analysis offers an in-depth look at the financial ecosystem fueling the explosive growth of the cell and gene therapy (CGT) industry — a market defined by breakthrough innovation, global competition, and evolving funding landscapes. The report is released in two installments, with the first part available now, covering deals through Q4 2024. The second installment, included with purchase, will be released in Fall 2025 and cover activity through Q3 2025. "Many categories of deals, such as collaborations, distribution/co-marketing, and manufacturing/supply chain, have shown a long-term pattern of growth," said Justin Saeks, senior market analyst at Kalorama Information. "And there's reason for optimism regarding continued investments. Cell and gene therapy-related companies have continued to receive huge amounts of investment." Key Insights from the Report: Over 2,000 CGT-related deals analyzed, with quarterly trends tracked from Q1 2021 to Q4 2024 Despite a tighter funding environment, 2024 investment reached an estimated $39 billion, with a sharp Q4 uptick Top dealmakers include Astellas, Bristol Myers Squibb, Ginkgo Bioworks, Charles River, and Eli Lilly Deal types covered: VC/PE, IPO/SPAC, licensing, tech transfer, acquisitions, supply chain partnerships, and more Global perspective includes detailed breakdowns by region — North America, Europe, and APAC Why This Matters Now The CGT market is maturing fast, with fluctuating investment trends, growing deal diversity, and strategic partnerships becoming essential to survival. In 2023 and 2024, firms faced a contraction in available capital — from $73 billion in 2021 down to $35 billion in 2023 — yet collaborative and manufacturing partnerships have been on the rise. This suggests that dealmaking is evolving, not disappearing. Who Should Purchase and Read This Report This report is essential for: Biotech and pharma execs seeking M&A or licensing opportunities VC/PE investors tracking funding cycles and active biotech targets Strategic planners and BD professionals looking to benchmark activity Consultants, CROs, and CMOs aligning services with market needs Regulatory and policy advisors assessing funding shifts and regional dynamics Strategic Use Cases Identify high-activity players and ideal partners for collaboration or acquisition Benchmark funding rounds and valuations for startups or expanding companies Inform R&D focus by tracking which technologies (e.g., CRISPR, AAV) are attracting deals Support global expansion using regional deal patterns and emerging market trends Strengthen regulatory preparedness by understanding the impact of policy shifts on financing Companion Report Available This report pairs with Kalorama's Cell and Gene Therapy Market Dynamics by Disease Type: Development, Trends, and Forecasts, 2024–2030 (4th Edition) — offering disease-area breakdowns of the CGT landscape in oncology, neurology, musculoskeletal, and beyond. Get the Report Download or purchase the report here:Cell and Gene Therapy Market Deals: Investments, M&As, and Partnerships, 2021–2025 (3rd Edition) Explore the companion report:Cell and Gene Therapy Market Dynamics by Disease Type, 2024–2030 (4th Edition) About Kalorama InformationKalorama Information, part of Science and Medicine Group, is a trusted source of market research in the life sciences. With a focus on in vitro diagnostics, biotechnology, and medical devices, Kalorama reports are used by top healthcare companies, government agencies, and investment firms worldwide. For purchase or custom consultation, contact:Sheri DavieKalorama Information Sales For media inquiries please contact:Alisa AlvichMarketing View original content to download multimedia: SOURCE Kalorama Information Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Should You Forget Intel and Buy This Millionaire-Maker Stock Instead?
Should You Forget Intel and Buy This Millionaire-Maker Stock Instead?

Yahoo

time2 hours ago

  • Yahoo

Should You Forget Intel and Buy This Millionaire-Maker Stock Instead?

Intel faces tough existential challenges. Broadcom operates a more diversified business, which is tethered to the AI market. It could generate much bigger gains than Intel over the next few years. 10 stocks we like better than Broadcom › Once upon a time, Intel (NASDAQ: INTC) was a millionaire-maker stock. If you had invested $10,000 in its initial public offering (IPO) in 1971, it would be worth $10.3 million today. However, that investment briefly blossomed to $37.9 million when the stock closed at its record high on Aug. 28, 2000. Yet Intel hasn't generated any millionaire-making gains since then. Over the past decade, the chipmaker struggled with market share losses to AMD in the x86 CPU market, persistent shortages and delays, and abrupt strategic shifts under four different CEOs. It couldn't leverage its dominance of the PC and server CPU markets to expand into the higher-growth mobile and AI chip markets, while its own foundries fell behind Taiwan Semiconductor Manufacturing (TSMC for short) in the race to produce smaller and denser chips. From 2024 to 2027, analysts expect Intel's revenue to have an anemic compound annual growth rate (CAGR) of 2% as the company's new CEO, Lip-Bu Tan, tries to bolster its engineering capabilities, develop more CPUs with integrated AI features, strengthen the foundry business, and streamline spending. Analysts expect Intel to stay unprofitable in 2025 as it spins all those plates, but they expect it to turn profitable again in 2026 and grow its net income more than sevenfold in 2027. That's an optimistic outlook, but Intel could struggle to balance the rollout of its latest 18A chips with its cost-cutting -- which includes the divestments of its noncore assets, layoffs, and its dependence on TSMC to manufacture some of its new 2nm CPUs. The stock also still looks overvalued relative to its peers at 74 times its forward adjusted earnings. So instead of betting on Intel's eventual recovery, it might be smarter to stick with another millionaire-maker semiconductor stock with a brighter future: Broadcom (NASDAQ: AVGO). Avago Technologies, the chipmaker that acquired the original Broadcom and inherited its brand in 2016, went public in 2009 at a split-adjusted price of $1.50 per share. A $10,000 investment in that IPO would be worth $1.63 million today. Prior to acquiring Broadcom, Avago produced a wide range of wireless, storage, networking, optical, and radio frequency chips. The original Broadcom competed against Avago in the storage and networking markets, but it also sold a wider variety of mobile, multimedia, and Wi-Fi/Bluetooth combo chips. By combining those two businesses, the "new" Broadcom supplied a diverse mix of essential chips for its enterprise, industrial, and mobile customers. Unlike Intel, which manufactures most of its own chips at its foundries, Broadcom is a fabless chipmaker that outsources its production to TSMC and other third-party foundries. That strategy is less capital-intensive and is better insulated from delays and shortages. Broadcom subsequently bought more companies, including Brocade, a provider of storage networking products, in 2017; the mainframe and enterprise software provider CA Technologies in 2018; Symantec's enterprise security business in 2019, and the cloud software giant VMware in 2023. Those acquisitions turned Broadcom into a more diversified tech company that generated 42% of its revenue from its infrastructure software business in fiscal 2024 (which ended last November). The remaining 58% came from its semiconductor solutions business. Most of the company's recent growth was driven by its sales of networking, optical, and custom accelerator chips to power the latest AI applications. In fiscal 2024, its sales of those AI-focused chips surged 220% to $12.2 billion and accounted for 24% of its top line. The rapid expansion of that business, which propelled its stock to fresh all-time highs last year, offset the slower growth of its non-AI chip and software businesses. From fiscal 2024 to fiscal 2027, analysts expect Broadcom's revenue and earnings per share to have a CAGR of 18% and 80%, respectively. That robust growth should be driven by its soaring sales of AI chips, its integration and expansion of VMware's cloud ecosystem, and ongoing buybacks. That's an impressive trajectory for a stock trading at 38 times its forward adjusted earnings, and it pays a forward yield of 1%. Intel suspended its dividend to stabilize cash flow last year. So if you're looking for a diversified tech play with plenty of exposure to the booming AI and cloud markets, Broadcom seems like a much better investment than Intel. While Intel might eventually recover as it gets its act together, it faces a tougher uphill battle than Broadcom, which doesn't face the same existential challenges as Intel. Before you buy stock in Broadcom, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Broadcom wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Leo Sun has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Advanced Micro Devices, Intel, and Taiwan Semiconductor Manufacturing. The Motley Fool recommends Broadcom and recommends the following options: short August 2025 $24 calls on Intel. The Motley Fool has a disclosure policy. Should You Forget Intel and Buy This Millionaire-Maker Stock Instead? was originally published by The Motley Fool

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store